Evidence map›Paper›PMID 39786588›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Modulation of PI3K/AKT signaling and DFT modeling via selected pharmaceutical compounds attenuates carrageenan-induced inflammation and oxidative stress in rats.

Ahmed A Abd-Rabou, Marwa Kamal, Hussam Y Alharbi, Majed S Aljohani, Mohamed A El-Atawy, Mohamed S Kishta

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Mechanism Through Which Antioxidant Polysaccharide fromMolecules (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Immunomodulatory Effects ofAntioxidants (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ahmed A Abd-RabouHormones Department, Medical Research and Clinical Studies Institute, National Research Centre, Giza, 12622, Egypt. ahmedchemia87@yahoo.com.ORCID 0000-0002-9875-7591
Marwa KamalDepartment of Histology and Cell Biology, Faculty of Medicine (Girls) (AFMG), Al-Azhar University, Cairo, 11754, Egypt.
Hussam Y AlharbiDepartment of Chemistry, Faculty of Science, Taibah University, Yanbu, Saudi Arabia.
Majed S AljohaniDepartment of Chemistry, Faculty of Science, Taibah University, Yanbu, Saudi Arabia.
Mohamed A El-AtawyDepartment of Chemistry, Faculty of Science, Taibah University, Yanbu, Saudi Arabia.
Mohamed S KishtaHormones Department, Medical Research and Clinical Studies Institute, National Research Centre, Giza, 12622, Egypt. kishtamsa@gmail.com.ORCID 0000-0002-2314-8820

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main goal of the current study is to estimate the in vivo anti-inflammatory/antioxidant ability of four selected pharmaceutical compounds: bisoprolol (Biso), piracetam (Pirc), clopidogrel (Clop), and cinnarizine (Cinna). Indomethacin (Indo) was used as a reference drug to perform a realistic comparison between the four compounds and the Indo in vivo through tracking PI3K/AKT signaling and computational chemistry via density functional theory (DFT) modeling to analyze the electrostatic potential across the molecule and provide insight into the regions for receptor binding of the studied compounds. To achieve the safe dose of these compounds, cytotoxicity was performed against isolated adipose tissue-derived mesenchymal stem cells (ADMSCs) using MTT assay. In vivo determination of anti-inflammatory/antioxidant biochemical and genetic parameters of the tested compounds against rats' paw carrageenan (Carg)-induced inflammation was assessed. The data showed that there was no significant different in cell viability of ADMSCs until dose 10 µg/ml, so we used this concentration for in vivo experiments. Carg high significantly increased the volume of the paw edema at 120 min and 180 min compared to the control group (p < 0.01). Cinna (10 mg/kg), relatively similar to Indo, was the most anti-inflammatory compound among others, followed by Clop and Pirc, where they decreased the volume of the paw edema significantly (p < 0.01) at 120 min and 180 min compared to the Carg-group. Microscopic examination confirmed the above results indicating that paw tissue of Carg-group shows edema formation and massive inflammation compared with control. In comparison to the control group, Carg high significantly increased the malondialdehyde (MDA) levels (p < 0.01), whereas, at the concentration 10 mg/kg of the tested compounds, the MDA concentrations significantly reduced, especially the Clop, Cinna, and Indo-treated groups. On the contrary, total antioxidant capacity (TAC) and 5-lipoxygenase (5-LOP) concentrations were significantly decreased in Carg-group (p < 0.01) compared with control. Cyclooxygenase-2 (COX-2), phosphoinositide 3-kinase (PI3k), and protein kinase B (AKT) gene expressions were high and significantly upregulated in Carg-group compared to control, while the tested compounds downregulated their expressions compared to the Carg-group. Moreover, COX-2, interleukins (IL-10/IL-6/IL-4), PI3k, and AKT protein concentrations were high and significantly increased in Carg-group compared to control, however the tested compounds were high and significantly decreased their concentrations compared to the Carg-group. DFT modeling aligned with the biochemical data and indicated that Cinna emerges as the most reactive drug with high polarizability (302.741 a.u.), a relative small FMOs energy gap (ΔE 5.002 eV), relative low molecular hardness (2.501 eV), relative high softness (0.400 eV

Indexed as

Anti-Inflammatory AgentsAntioxidantsInflammationOxidative StressPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAnimalsCarrageenanCell SurvivalEdemaMaleMesenchymal Stem CellsRatsRats, WistarSignal TransductionAnti-Inflammatory AgentsAntioxidantsCarrageenanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktBisoprololCinnarizineClopidogrelDFT modelingInflammationPI3K/AKT signalingPiracetam

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.